Added to YB: 2026-09-11
Pitch date: 2026-09-09
RLAY [neutral]
Relay Therapeutics, Inc.
Author Info
No bio for this author
Company Info
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications.
Market Cap
$4.1B
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-10.52
P/E
-11.88
EV/Sales
310.04
Sector
Biotechnology
Category
growth
Biotech Presentations, Wells Fargo Day 1 section 1 - Relay Therapeutics, Inc.
RLAY (quick overview): Relay Therapeutics has two substantial shots on goal with Zovega: vascular anomalies may provide the faster regulatory path, while breast cancer could represent the larger commercial opportunity if the clean safety profile is confirmed in Phase 3. Management cited roughly 11 months of progression-free survival post-CDK4/6 versus about 5.5 months for capivasertib in a similar setting, along with claimed tolerability advantages. Early vascular-anomaly data showed an approximately 60% response rate.
Read full article (1 min)